Generate’s protein design platform draws $370M series B

Generate’s protein design platform has attracted one of the largest venture rounds of 2021 a little more than a year after the company’s launch, and it’s planning to use the funding to rapidly scale its capabilities. 

Launched by Flagship Pioneering, Generate Biomedicines Inc. raised $370 million in a series B round from Flagship and institutional co-investors including a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), the Alaska Permanent Fund, Altitude Life Science Venture, Arch Venture Partners, Fidelity Management & Research Co., Morningside Venture and T. Rowe Price Associates...